Article Sidebar

PDF
Date Published: 29/06/2023
Online Published: 29/06/2023
Abstract Views: 449
Views PDF: 215
DOI: https://doi.org/10.58490/ctump.2023i60.565
Issue
No. 60 (2023)
Section
Article
How to Cite
Nguyen, H. H., Tran , N. T. H., Dinh , B. H., Huynh, T. T., & Mai, H. N. T. (2023). RATE AND RESULTS OF HYPOKALEMIA TREATMENT IN PATIENTS WITH CHRONIC RENAL FAILURE UNDERGOING PERITONEAL DIALYSIS AT CAN THO GENERAL HOSPITAL. Cantho Journal of Medicine and Pharmacy, 60, 79-86. https://doi.org/10.58490/ctump.2023i60.565

RATE AND RESULTS OF HYPOKALEMIA TREATMENT IN PATIENTS WITH CHRONIC RENAL FAILURE UNDERGOING PERITONEAL DIALYSIS AT CAN THO GENERAL HOSPITAL

Hoàng Huy Nguyen1,, Nguyen Thuy Hien Tran 1, Bat Hung Dinh 1, Trong That Huynh2, Huynh Ngoc Tan Mai2
1 Can Tho University Of Medicine And Pharmacy
2 Can Tho University of Medicine and Pharmacy

Main Article Content

Abstract

Background: Hypokalemia is a common complication (7-36%) in patients with chronic renal failure undergoing peritoneal dialysis. In Vietnam, this rate at Cho Ray Hospital was 42%, and at Can Tho General Hospital was 48%. However, these investigations have not investigated hypokalemia treatment in patients with chronic renal failure on peritoneal dialysis. Objectives: 1). To determine the rate of hypokalemia and the related factors; 2). To evaluate the results of hypokalemia and persistent hypokalemia treatment in patients with chronic renal failure undergoing peritoneal dialysis at Can Tho General Hospital. Materials and method: A descriptive crosssectional and prospective study was conducted on 66 patients with chronic renal failure undergoing cycle peritoneal dialysis had been treated for outpatient treatment at Can Tho General Hospital from 25/6/2021 to 25/6/2022. Results: There was 27.3% of patients had hypokalemia. After one month of treatment with potassium chloride, 44.4% of the patients reached the potassium target, with the mean difference before and after treatment being -0.41mmol/L. The mean difference before and after one month of treatment in the patients with persistent hypokalemia with spironolactone was -0.21 ± 0.40 mmol/L but not significant with p = 0.204. Conclusions: The incidence of hypokalemia was high in patients with chronic renal failure undergoing peritoneal dialysis. The treatment of hypokalemia with potassium chloride was effective. However, there was a group of patients with persistent hypokalemia requiring alternatives. Among the methods, spironolactone is a potential therapy to treat persistent hypokalemia patients.

Article Details

Keywords

chronic renal failure, peritoneal dialysis, hypokalemia, persistent hypokalemia, spironolactone

References

1. Tziviskou E, Musso C, Bellizzi V, et al. Prevalence and pathogenesis of hypokalemia in patients on chronic peritoneal dialysis: one center's experience and review of the literature. Int Urol Nephrol. 2003. 35(3), 429-34, doi: 10.1023/b: urol.0000022867.93739.03.
2. Jung JY, Chang JH, Lee HH, et al. De novo hypokalemia in incident peritoneal dialysis patients: a 1year observational study. Electrolyte Blood Press. 2009. 7(2), 73-78, doi: 10.5049/EBP.2009.7.2.73.
3. Davies SJ, Zhao J, Morgenstern H, et al. Low Serum Potassium Levels and Clinical Outcomes in Peritoneal Dialysis-International Results from PDOPPS. Kidney Int Rep. 2020. 6(2), 313-324, doi: 10.1016/j.ekir.2020.11.021.
4. Perl J, Davies SJ, Lambie M, et al. The Peritoneal Dialysis Outcomes and Practice Patterns Study (PDOPPS): Unifying Efforts to Inform Practice and Improve Global Outcomes in Peritoneal Dialysis. Perit Dial Int. 2016. 36(3), 297-307, doi: 10.3747/pdi.2014.00288.
5. Nguyễn Hùng, Nguyễn Thị Phòng, Đỗ Anh Đào và cộng sự. Khảo sát các biến chứng của phương pháp thẩm phân phúc mạc liên tục ngoại trú ở bệnh thận giai đoạn cuối. Y học thành phố Hồ Chí Minh. 2011. 15, 45-50.
6. Gennari FJ. Hypokalemia. N Engl J Med. 1998. 339(7), 451-458, doi:
10.1056/NEJM199808133390707.
7. Bộ Y Tế. Hướng dẫn chẩn đoán điều trị hồi sức tích cực. Nhà xuất bản Y học, Hà Nội. 2015. 184-187.
8. Villa-Zapata L, Carhart BS, Horn JR, et al. Serum potassium changes due to concomitant ACEI/ARB and spironolactone therapy: A systematic review and meta-analysis. Am J Health Syst Pharm. 2021. 78(24), 2245-2255, doi: 10.1093/ajhp/zxab215.
9. Virojanawat M, Puapatanakul P, Chuengsaman P, et al. Hypokalemia in peritoneal dialysis patients in Thailand: the pivotal role of low potassium intake. International urology and nephrology. 2021. 53(7), 1463-1471, doi: 10.1007/s11255-020-02773-8.
10. Danh Mới. Nghiên cứu đặc điểm lâm sàng, cận lâm sàng và đánh giá kết quả điều trị của phương pháp thẩm phân phúc mạc ở bệnh nhân suy thận giai đoạn cuối tại Bệnh viện Đa khoa Thành phố Cần Thơ năm 2016 – 2017. Luận án đại học. Đại học Y Dược Cần Thơ. 2017.
11. Hawkins RC. Gender and age as risk factors for hypokalemia and hyperkalemia in a multiethnic Asian population. Clinica Chimica Acta. 2003. 331(1-2), 171-172, doi: 10.1016/s00098981(03)00112-8.
12. Langote A, Hiremath S, Ruzicka M, et al. Spironolactone is effective in treating hypokalemia among peritoneal dialysis patients. PLoS One. 12(11), e0187269, doi: 10.1371/journal.pone.0187269.
13. Dørup I, Clausen T. Effects of adrenal steroids on the concentration of Na (+)-K+ pumps in rat skeletal muscle. The Journal of endocrinology. 1997. 152(1), 49-57, doi: 10.1677/joe.0.1520049.